These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
575 related articles for article (PubMed ID: 33368052)
1. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies. Dulgar O; Kutuk T; Eroglu Z Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052 [TBL] [Abstract][Full Text] [Related]
2. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure? Schummer P; Schilling B; Gesierich A Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332 [TBL] [Abstract][Full Text] [Related]
4. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322 [TBL] [Abstract][Full Text] [Related]
5. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433 [TBL] [Abstract][Full Text] [Related]
6. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351 [TBL] [Abstract][Full Text] [Related]
7. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting. Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054 [TBL] [Abstract][Full Text] [Related]
8. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Hassel JC; Buder-Bakhaya K; Bender C; Zimmer L; Weide B; Loquai C; Ugurel S; Slynko A; Gutzmer R; Cancer Med; 2018 Jan; 7(1):95-104. PubMed ID: 29266761 [TBL] [Abstract][Full Text] [Related]
9. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data. Wu B; Shi L JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281 [TBL] [Abstract][Full Text] [Related]
10. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Devji T; Levine O; Neupane B; Beyene J; Xie F JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543 [TBL] [Abstract][Full Text] [Related]
11. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Lim SY; Menzies AM; Rizos H Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695 [TBL] [Abstract][Full Text] [Related]
13. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. Samlowski W; Adajar C BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688 [TBL] [Abstract][Full Text] [Related]
14. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? Welsh SJ; Rizos H; Scolyer RA; Long GV Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329 [TBL] [Abstract][Full Text] [Related]
15. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. Zhou AY; Johnson DB Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871 [TBL] [Abstract][Full Text] [Related]
16. First-line immunotherapy versus targeted therapy in patients with Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375 [No Abstract] [Full Text] [Related]
17. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. Fujimura T; Hidaka T; Kambayashi Y; Aiba S Expert Opin Investig Drugs; 2019 Feb; 28(2):143-148. PubMed ID: 30556435 [TBL] [Abstract][Full Text] [Related]